LSA
BMRN icon

L & S Advisors’s BioMarin Pharmaceuticals BMRN Stock Holding History

L & S Advisors’s Portfolio BMRN Stock Details BMRN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q2 		– Sell
-8,616
Closed -$838K – 308
2023
Q1 		$838K Sell
8,616
-4,095
-32% -$425K 0.12% 170
2022
Q4 		$1.32M Buy
12,711
+3,331
+36% +$313K 0.24% 100
2022
Q3 		$795K Buy
+9,380
New +$835K 0.14% 141
2020
Q3 		– Sell
-8,859
Closed -$1.09M – 302
2020
Q2 		$1.09M Buy
8,859
+419
+5% +$41.6K 0.16% 160
2020
Q1 		$713K Sell
8,440
-125
-1% -$10.8K 0.13% 144
2019
Q4 		$724K Buy
8,565
+1,450
+20% +$110K 0.09% 183
2019
Q3 		$480K Sell
7,115
-3,099
-30% -$239K 0.07% 238
2019
Q2 		$875K Buy
10,214
+729
+8% +$62.4K 0.12% 191
2019
Q1 		$843K Buy
9,485
+1,690
+22% +$157K 0.11% 185
2018
Q4 		$664K Sell
7,795
-785
-9% -$74.7K 0.12% 161
2018
Q3 		$832K Buy
8,580
+1,625
+23% +$162K 0.11% 168
2018
Q2 		$655K Buy
+6,955
New +$609K 0.11% 178

Other funds holding BMRN

Primecap Management
Primecap Management Pasadena, California $127B AUM 44.11% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Dodge & Cox
Dodge & Cox San Francisco, California $182B AUM 14.68% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Capital Research Global Investors
Capital Research Global Investors Los Angeles, California $645B AUM 30.41% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Ameriprise
Ameriprise Minneapolis, Minnesota $432B AUM 30.22% 1-Year Est. Return
Viking Global Investors
Viking Global Investors Stamford, Connecticut $35.7B AUM 21.3% 1-Year Est. Return
ACA
Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return

L & S Advisors's BMRN Position: Q2 2023 in Review

L & S Advisors sold out of BioMarin Pharmaceuticals (BMRN) in Q2 2023, closing a stake of 8,616 shares — an estimated $838K sold.

L & S Advisors first reported a position in BMRN in Q2 2018 and held it in 12 quarters. The position peaked at $1.32M in Q4 2022. 558 funds tracked by Wall St. Rank hold BMRN as of Q2 2023.

  • L & S Advisors reported no remaining BioMarin Pharmaceuticals position as of Q2 2023 after selling out during the quarter.
  • L & S Advisors sold 8,616 BioMarin Pharmaceuticals shares in Q2 2023, an estimated $838K.
  • L & S Advisors first reported a position in BioMarin Pharmaceuticals in Q2 2018 and held it in 12 quarters.
  • L & S Advisors's BioMarin Pharmaceuticals position peaked at $1.32M in Q4 2022.
  • 558 funds tracked by Wall St. Rank held BioMarin Pharmaceuticals as of Q2 2023.

Based on L & S Advisors's 13F filing for Q2 2023, filed 14 Aug 2023.